Tryptamine Therapeutics Past Earnings Performance
Past criteria checks 0/6
Tryptamine Therapeutics has been growing earnings at an average annual rate of 0.3%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been growing at an average rate of 176.4% per year.
Key information
0.3%
Earnings growth rate
56.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | 176.4% |
| Return on equity | -131.2% |
| Net Margin | -555.4% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Tryptamine Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1 | -7 | 4 | 0 |
| 29 Feb 24 | 0 | -5 | 3 | 1 |
| 30 Nov 23 | 0 | -5 | 3 | 2 |
| 31 Aug 23 | 0 | -6 | 2 | 0 |
| 31 May 23 | 0 | -7 | 2 | 4 |
| 28 Feb 23 | 0 | -6 | 2 | 4 |
| 30 Nov 22 | 0 | -7 | 3 | 4 |
| 31 Aug 22 | 0 | -8 | 5 | 3 |
| 31 May 22 | 0 | -9 | 6 | 2 |
| 28 Feb 22 | 0 | -11 | 8 | 2 |
| 30 Nov 21 | 0 | -12 | 9 | 2 |
| 31 Aug 21 | 0 | -9 | 7 | 1 |
| 31 May 21 | 0 | -6 | 5 | 0 |
Quality Earnings: TYP is currently unprofitable.
Growing Profit Margin: TYP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TYP is unprofitable, but has reduced losses over the past 5 years at a rate of 0.3% per year.
Accelerating Growth: Unable to compare TYP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TYP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (46.5%).
Return on Equity
High ROE: TYP has a negative Return on Equity (-131.15%), as it is currently unprofitable.